Concepedia

Stephen E. Zale

SE

17

Publications

3.1K

Citations

16

H-Index

1982

Active since

Affiliations

Massachusetts Institute of Technology(Current)

Alkermes (United States)

Alkermes (Ireland)

AstraZeneca (United Kingdom)

University of Puerto Rico at Río Piedras

Stephen E. Zale is an author at Massachusetts Institute of Technology specializing in engineering, medicine, and nanomedicine.

Top concepts

Publications per year

1982–2017

17

Publications

17

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali et al. · Science Translational Medicine · 2012 · 1.1K citations

Membrane-Based Affinity Technology for Commercial Scale Purifications

Steve Brandt, Randal A. Goffe, Stephen B. Kessler et al. · Nature Biotechnology · 1988 · 298 citations

, , +1

Why does ribonuclease irreversibly inactivate at high temperatures?

Stephen E. Zale, Alexander M. Klibanov · Biochemistry · 1986 · 274 citations

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan et al. · Clinical Cancer Research · 2016 · 262 citations

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Susan Ashton, Young Ho Song, Elaine Cadogan et al. · Science Translational Medicine · 2016 · 213 citations

Rows per page

1–5 of 17